Institution
Detroit Receiving Hospital
Healthcare•Detroit, Michigan, United States•
About: Detroit Receiving Hospital is a healthcare organization based out in Detroit, Michigan, United States. It is known for research contribution in the topics: Vancomycin & Population. The organization has 877 authors who have published 850 publications receiving 37202 citations. The organization is also known as: Detroit General.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Despite an ethical and legal consensus regarding the right of patients or their surrogates to refuse life-prolonging therapy, surveys show that dying patients in hospitals in the United States frequently receive unwanted interventions.
Abstract: Despite an ethical and legal consensus regarding the right of patients or their surrogates to refuse life-prolonging therapy, surveys show that dying patients in hospitals in the United States frequently receive unwanted interventions.1,2 One reason for this may be a lack of training among physicians and nurses in the clinical aspects of withdrawing intensive life support. Staff members are highly skilled in aggressive life-extending treatment, and some hospitals now have services specializing in palliative care for patients forgoing life-extending treatment. But there may be no one specifically trained in managing the transition from one style of care to the . . .
268 citations
••
Harvard University1, University of Pittsburgh2, Yale University3, Veterans Health Administration4, Pennsylvania State University5, University of Maryland, Baltimore6, University of Alabama at Birmingham7, University of California, Irvine8, Eli Lilly and Company9, Detroit Receiving Hospital10, Ohio State University11
TL;DR: The provision of procalcitonin assay results, along with instructions on their interpretation, to emergency department and hospital‐based clinicians did not result in less use of antibiotics than did usual care among patients with suspected lower respiratory tract infection.
Abstract: Background The effect of procalcitonin-guided use of antibiotics on treatment for suspected lower respiratory tract infection is unclear. Methods In 14 U.S. hospitals with high adherence to quality measures for the treatment of pneumonia, we provided guidance for clinicians about national clinical practice recommendations for the treatment of lower respiratory tract infections and the interpretation of procalcitonin assays. We then randomly assigned patients who presented to the emergency department with a suspected lower respiratory tract infection and for whom the treating physician was uncertain whether antibiotic therapy was indicated to one of two groups: the procalcitonin group, in which the treating clinicians were provided with real-time initial (and serial, if the patient was hospitalized) procalcitonin assay results and an antibiotic use guideline with graded recommendations based on four tiers of procalcitonin levels, or the usual-care group. We hypothesized that within 30 days after e...
268 citations
••
263 citations
••
University of Maryland, Baltimore1, Detroit Receiving Hospital2, Howard University3, Rush University Medical Center4, Virginia Commonwealth University5, University of Texas Health Science Center at Houston6, Medical University of South Carolina7, Veterans Health Administration8, Louisiana State University9
TL;DR: Atenolol, captopril, and verapamil sustained release therapy was associated with goal blood pressure achievement during the first treatment period and during the second treatment period, and side effects were minimal and comparable for all three drugs.
Abstract: A double-blind, positively controlled, forced dose titration study comparing the efficacy and safety of atenolol, captopril, and verapamil sustained release as single agents in the treatment of black patients with mild to moderate hypertension (diastolic blood pressure, 95 to 114 mm Hg) was conducted. A total of 394 patients were randomized to one of the three therapies. Mean blood pressures during a 2- to 4-week placebo treatment period (baseline) ranged from 100.4 to 100.7 mm Hg diastolic and 151.7 to 152.5 mm Hg systolic for the three groups. Of the patients, 355 (of whom 345 had assessable data) completed the first treatment period, which consisted of therapy with either 50 mg/d of atenolol, 25 mg every 12 hours of captopril, or 240 mg/d of verapamil sustained release. During the second 4-week treatment period, which 319 patients completed (307 assessable), half of the patients had their antihypertensive medication increased and the other half continued the same dose. Goal blood pressure was defined as a supine diastolic pressure of less than 90 mm Hg or a 10—mm Hg or greater drop in supine diastolic blood pressure from pretreatment levels. Atenolol, captopril, and verapamil sustained release therapy was associated with goal blood pressure achievement during the first treatment period 55.1%, 43.8%, and 65.2% of the time, respectively, and during the second treatment period 59.6%, 57.1%, and 73.0% of the time. Side effects were minimal and comparable for all three drugs. (Arch Intern Med.1990;150:1707-1713)
252 citations
•
TL;DR: Improvement in response to skin-test antigens and taste acuity was observed after zinc supplementation, and a mild zinc deficiency appears to be a significant clinical problem in free-living elderly people.
246 citations
Authors
Showing all 878 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ronald N. Jones | 109 | 1169 | 54206 |
Husseini K. Manji | 104 | 283 | 36624 |
Paul E. Marik | 89 | 621 | 32719 |
Michael J. Rybak | 77 | 420 | 24816 |
John M. Carethers | 52 | 199 | 9723 |
Renee C. LeBoeuf | 50 | 112 | 7017 |
John W. Devlin | 48 | 234 | 11941 |
Charles E. Lucas | 47 | 260 | 6768 |
Jan Paul Muizelaar | 47 | 99 | 10934 |
Vincent H. Tam | 45 | 184 | 7276 |
Berton R. Moed | 42 | 154 | 5311 |
James T. Fitzgerald | 42 | 120 | 7989 |
David Edelman | 38 | 165 | 5346 |
Donald P. Levine | 38 | 87 | 11611 |
Scott A. Dulchavsky | 38 | 130 | 5669 |